MDACC Study No:2009-0878 ( NCT No: NCT01021748)
Title:A Phase I Study of Oral MK-2206 in Combination with Oral AZD6244 in Patients with Locally Advanced or Metastatic Solid Tumors (010-03)
Principal Investigator:Chris Garrett
Treatment Agent:AZD6244; MK-2206
Study Status:Terminated
Study Description:The goal of the first part (Part A) of this clinical research study is to find
the highest tolerated dose and best treatment schedule of the combination of
MK-2206 and AZD6244 that can be given safely to patients with advanced cancer.

The goal of the second part (Part B) is to further test the highest tolerated
dose of MK-2206 and AZD6244 when given to patients with cancer of the pancreas,
colon, rectum, or melanoma (a type of skin cancer).
Hide details for General InformationGeneral Information

Disease Group:Colorectum; Melanoma; Pancreas; Solid Tumors
Phase of Study:Phase I
Treatment Agents:AZD6244
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:Not applicable.
Supported By:Merck & Co., Inc.
Return Visit:Return visit schedule varies depending upon the cycle. Cycle 1 may require up
to 13 study visits, depending upon assigned MK-2206 dosing schedule. Cycle 2
requires 4 study visits, and subsequent cycles require 1 study visit per cycle.
Home Care:Both study drugs are oral so participants may self administer the drugs at

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Chris Garrett
Dept:Gastrointestinal Medical Oncology
For Clinical Trial Enrollment:713-792-2828
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults